Minsheng Zhang

This inventor holds 33 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Eli Lilly and Company, Jiangsu Hengrui Medicine Company Ltd., Bristol-Myers Squibb Compnay. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Minsheng Zhang. Retrieved from https://idiyas.com/inventor/minsheng-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 5.8

ph-index = 7

Forward Citations = 137(Granted Patents)

Location History:

Nutley, NJ (US) (2000 - 2001)
Greenbrook, NJ (US) (2015 - 2019)
Shanghai, CN (2020 - 2021)
Warren, NJ (US) (2001 - 2022)

Company Filing History:

11 out of 4,514

Eli Lilly and Company

patents

7 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

6 out of 3,742

Bristol-Myers Squibb Compnay

patents

4. 4 out of 100

Shanghai Hengrui Pharmaceutical Co., Ltd.

Eternity Bioscience Inc.

patent

8. 1 out of 11

Impact Therapeutics, Inc.

patents

9. 1 out of 10

Jiangsu Hansoh Pharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Benzimidazole Derivatives

Protein Kinase Inhibitors

Thyroid Receptor Ligands

Antithrombotic Agents

Benzofuran Derivatives

Fluoroalkyl Compounds

Dihydropyrimidone Inhibitors

Quinazolinediones

Pyridine-Based Ligands

Aminopyridazinone Compounds

Ethynyl Heterobicyclic Compounds

Thrombin Inhibitors

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187684 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof (2025-01-07),

2. 11512055 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof (2022-11-29),

3. 11059811 - Benzofuran derivative, preparation method thereof and use thereof in medicine (2021-07-13),

4. 10759787 - Benzofuran derivative, preparation method thereof and use thereof in medicine (2020-09-01),

5. 10323037 - Aminopyridazinone compounds as protein kinase inhibitors (2019-06-18),

6. 10144737 - Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors (2018-12-04),

7. 9951077 - Aminopyridazinone compounds as protein kinase inhibitors (2018-04-24),

8. 9458140 - Furanone compounds as kinase inhibitors (2016-10-04),

9. 9090568 - Quinazolinediones and their use (2015-07-28),

10. 8951993 - Phosphorus containing compounds as protein kinase inhibitors (2015-02-10),

11. 8263659 - Thyroid receptor ligands (2012-09-11),

12. 7858658 - Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof (2010-12-28),

13. 7557143 - Thyroid receptor ligands (2009-07-07),

14. 7547725 - Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof (2009-06-16),

15. 7300951 - Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof (2007-11-27),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I am here to help you with the requested article about inventor Minsheng Zhang.

Title: Unveiling the Innovations of Inventor Minsheng Zhang

Introduction:

In the realm of inventors, Minsheng Zhang stands out as a prolific mind contributing significantly to the field of pharmaceuticals with his groundbreaking patents. Hailing from Warren, NJ (US), he has left a mark with a remarkable tally of 32 patents to his credit.

Latest Patents:

Among his latest patents, one noteworthy invention is related to benzimidazole derivatives that serve as modulators of the retinoid-related orphan receptor gamma (RORγ). These compounds hold promising potential in the treatment of RORγ-mediated diseases and disorders.

Additionally, Minsheng Zhang's work on benzofuran derivatives, their preparation methods, and medicinal uses showcase his innovative prowess in developing therapeutic agents, especially in the realm of cancer treatment.

Career Highlights:

Throughout his career, Minsheng Zhang has made significant contributions while working with esteemed companies such as Eli Lilly and Company and Bristol-Myers Squibb Company. His dedication to innovation and research has shaped the pharmaceutical landscape, pushing boundaries for the betterment of healthcare.

Collaborations:

In his journey of innovation, Minsheng Zhang has collaborated with accomplished individuals in the field, including Richard Waltz Harper and Ho-Shen Lin. These collaborations have fostered a creative environment where ideas thrive, leading to impactful inventions that benefit society.

Conclusion:

In conclusion, Minsheng Zhang's relentless pursuit of innovation and his remarkable portfolio of patents underscore his influence in the pharmaceutical domain. His inventions not only demonstrate scientific excellence but also offer hope for the future of healthcare through novel therapeutic approaches.

Profile summary based on public USPTO records.